HEM Pharma Inc. Logo

HEM Pharma Inc.

Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.

376270 | KO

Overview

Corporate Details

ISIN(s):
KR7376270005
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 711호, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HEM Pharma Inc. is a biotechnology company specializing in human microbiome research and technology. The company develops personalized healthcare solutions, probiotics, health functional foods, and Live Biotherapeutic Products (LBPs). Its core competency lies in its proprietary Personalized Microbiome Analysis System (PMAS), a screening platform used to identify and develop customized microbial solutions based on multi-omics and metabolome analysis. HEM Pharma also utilizes its MBR high-concentration fermentation technology for efficient production and offers Contract Development and Manufacturing Organization (CDMO) services through its GMP-certified facilities, supporting the entire lifecycle of microbiome-based products from research to manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-21 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.4 MB
2025-05-08 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 4.9 KB
2025-04-23 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 62.3 KB
2025-04-03 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.5 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.2 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.3 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.2 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.0 KB
2025-03-31 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB

Automate Your Workflow. Get a real-time feed of all HEM Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEM Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEM Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.